Share Name Share Symbol Market Type Share ISIN Share Description
Circassia Pharmaceuticals Plc LSE:CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.15 -0.9% 16.50 210,709 15:34:11
Bid Price Offer Price High Price Low Price Open Price
16.40 16.60 16.50 16.00 16.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.30 -55.80 -34.00 61
Last Trade Time Trade Type Trade Size Trade Price Currency
17:05:29 O 27 16.499 GBX

Circassia Pharmaceuticals (CIR) Latest News

More Circassia Pharmaceuticals News
Circassia Pharmaceuticals Takeover Rumours

Circassia Pharmaceuticals (CIR) Share Charts

1 Year Circassia Pharmaceuticals Chart

1 Year Circassia Pharmaceuticals Chart

1 Month Circassia Pharmaceuticals Chart

1 Month Circassia Pharmaceuticals Chart

Intraday Circassia Pharmaceuticals Chart

Intraday Circassia Pharmaceuticals Chart

Circassia Pharmaceuticals (CIR) Discussions and Chat

Circassia Pharmaceuticals Forums and Chat

Date Time Title Posts
01/10/201916:15Circassia Pharma PLC 472
20/10/200610:49Capricorn Resouces PLC - 50% premium in half a day811
10/2/200515:35100 % on no time12

Add a New Thread

Circassia Pharmaceuticals (CIR) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Circassia Pharmaceuticals trades in real-time

Circassia Pharmaceuticals (CIR) Top Chat Posts

Circassia Pharmaceuticals Daily Update: Circassia Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker CIR. The last closing price for Circassia Pharmaceuticals was 16.65p.
Circassia Pharmaceuticals Plc has a 4 week average price of 15p and a 12 week average price of 15p.
The 1 year high share price is 78.20p while the 1 year low share price is currently 13.25p.
There are currently 374,870,649 shares in issue and the average daily traded volume is 2,109,601 shares. The market capitalisation of Circassia Pharmaceuticals Plc is £60,729,045.14.
the abbot: I think as the latest interview this is well worth watching again, Steve certainly doesn't look like a man worried, indeed I would say he seems very happy with how things are going, all except the share price that is, but then at the time this was recorded I be he knew that woodford were going to be reducing. Circassia sets platform for strong growth in 2019 after period of consolidation [...]
seesawpat: Couldn't agree more Abbot. Share price 18p and they're giving themselves options to buy at 0.008p! Snouts in troughs - they haven't even bothered to tell us what the share performance has to be in order for these to vest.
the abbot: What a load of idiots these directors are, share price on the floor and they are still issuing themselves options, sack the lot of them the useless freeloaders. Think they can hide these with an after hours RNS, idiots
pre: so 2 issues here which create uncertainty and may affect share price: 1. woodfords holding of 28% by far the largest...if he sells on the market this could create significant volatility, or will he find another home? 2. Final deferred payment of $100 million is due by 30 June 2019 to Astrazeneca - how are CIR going to raise this? more dilution for shareholders??
aspringo: Not that the attached is overly helpful but asked some question of Circassia and the reply is below. Understand its a standard response but thought they should know we're not happy..The Company is also disappointed with the share price decline, which has occurred despite a number of positive developments in the business announced in recent months.  In terms of the market, both the sector and a number of UK small / mid-cap companies have experienced significant turbulence, which is also likely impacted by wider global concerns.  In terms of managing the business, we announced full year results at the beginning of May, where the Company outlined recent progress and we remain focused on driving the business forward.   Thanks again for your note. Kind regards
the abbot: Certainly if nothing else the CEO is guilty of gross incompetence. They sit back in their ivory tower thinking they ,'deserve' their renumeration due to the level of other CEO salaries, however not all ceo's are made of the same stuff and some just don't come up to the mark. Steve Harris has shown himself to be failing, he has shown he cannot control his board from immediately selling vested options, thus sending a poor message to the market, he has shown that he controls, based on share price performance, a failing business and he has shown incompetence in being able to direct his brokers to protect the share price from shorters. He has made no attempt to rectify the position by either director purchases or buybacks. And has failed in his marketing to produce anything worthy to sell the business such as analysts notes or for example some Edison research. In fact mostly he has only used proactive investors in which the audio is rubbish and he just comes across as smug. In all ways possible, if I had a hand in this I would be recommending all shareholders to vote against his approval at the AGM and seek alternative competent management, with an IR department that does not place themselves above the shareholders. But acts to support requests in which to aid and further the business.
the abbot: I am confident the price will rise here now the shorter is reducing, add to that the 2 FDA approvals and the general synopsis of the company and I think any purchases made recently are going to shine for their investor owners. However, what I am not happy about, and have made my views blatently clear to the company Directors, is their own seeming disregard for the protection of their share price and the one central aim which should be to return shareholder value. The same shareholders that support the company when required. I find it amazing that the Directors have not placed their hands in their pockets and purchased any shares, maybe its because they have been gifted so many that they don't feel the need, although the last non exec immediately sold his gifted options at a price of £0.0008 (i.e. an outlay of just £62) for a total of £69,060.25. How can they not see value at 25p a share. I am always angered at companys that like to award themselves options at ridiculously low prices and then think it is ok to exercise those options for pence and sell for thousands, when they have delivered zero shareholder value. At the AGM this year I would vote against the renumneration and against the ability to use the issuing of shares to pay their contractors. These Directors need to start delivering. Please remember before somone points out 'why am I invested' it is not for the love of the directors or how the company is run, it is purely transactional, I believe the shareprice will rise and I think the drugs and FDA approvals gives the company a huge advantage over its competitors in a very large field of ailment this being COPD.
badger60: the abbotYep..... unfortunately these days many promising small caps are very poorly marketed and/or become the object of manipulation by nearly everybody (understandably) becomes a trader, and I'm not too good at that.The big money for me is (choosing the right stock) made by being patient. On balance I have done well over the years, but also taken a few chunky hits along the way. Hemogenyx imo is potentially a serious multibagger, but it has been unloved, overlooked and very badly handled by the market since it came in October 2017, and like CIR much of the the embedded value is in no way reflected in the share price or market cap. ......but that's what no pain, no gain is all about.Good luck here....ttfn.
gersemi: 6 hours ago Circassia slashes net cash outflow By Mark Robinson Drug developers require a steady stream of positive clinical updates to underpin market valuations. Circassia Pharmaceuticals (CIE) provided shareholders with precisely that a month ahead of these full-year figures when it revealed that US regulators had given the green light for two of its chronic obstructive pulmonary disease (COPD) treatments. It is too early to say whether the news has arrested the share price decline of the previous 12-months, but given that very few UK-sponsored drugs have been approved in the US in the past few years, so the news - particularly in relation to the Duaklir drug - would not have gone unnoticed amongst the sector heavyweights. The drugs are complementary in that patients using its existing COPD treatment Tudorza (which got the go-ahead for the inclusion of new clinical data on its label) can move on to Duaklir if their condition deteriorates without needing to change their inhaler device. Bloomberg consensus gives revenues of £64.5m for the December 2019 year-end, with an accompanying adjusted earnings loss of 7.6p a share, before £84.8m and a 5.2p loss in the following year. CIRCASSIA PHARMACEUTICALS (CIR) ORD PRICE: 32p MARKET VALUE: £ 120m TOUCH: 31.2-32p 12-MONTH HIGH: 98p LOW: 25p DIVIDEND YIELD: NIL PE RATIO: NA NET ASSET VALUE: 34p* NET CASH: £40.7m Year to 31 Dec Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2014 nil -44.0 -21 nil 2015 10.8 -62.8 -20 nil 2016 23.1 -38.8 -48 nil 2017 (restated) 46.3 -74.2 -19 nil 2018 48.3 -55.8 -14 nil % change +4 - - - Ex-div: - Payment: - *Includes intangible assets of £231m, or 61.5p a share. IC View Duaklir was initially approved in the European Union five years ago, but the US launch in the second half of 2019 is highly significant given the potential up-scale. With a new revenue stream in prospect, 2018 may come to be seen as a watershed for the company. Though the net cash-outflow fell by two-thirds to £18.8m, the continued backing by AstraZeneca (AZN), which boosted its holding to 19.9 per cent midway through last year, has been crucial. However, given the lowly free-float, shareholders may struggle to buy into the US growth story. Hold. Last IC view: Hold, 34p, 01 Apr 2019 end
the abbot: I expect we have a strong potential for a short squeeze on Wednesday, I just listened to the Proactive interview and you can clearly hear that Steve Harris is excited about the results, these will additionally be marketed to the investment community with the appropriate forward looking statements relating to the newly achieved FDA approvals. I am quite surprised that at this price the buys are not larger, however if a short is going to close, not sure how easy it is going to be to buy shares back in the market to replace the loaned ones, I think they will have to accept that the profits they see today on paper, are not going to be what they walk away with, any buying and the price will motor. Hate the term under the radar particularly with the recent broker reviews, but heh I'm fine with this, looking at the past performance and share price I am very happy to be starting my investment here at 30p a share.
Circassia Pharmaceuticals share price data is direct from the London Stock Exchange
Your Recent History
Circassia ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191013 21:04:13